MitoMarkers: Mitochondrial Dysfunction in Autism

Summary

Autism spectrum disorder is a neurodevelopmental disorder affecting 1 in 54 children in Canada. ASD is increasingly being associated with mitochondrial dysfunction, a condition that may intensify or influence ASD symptoms. Mitochondrial dysfunction in ASD can impact various biological processes, that influence the neurodevelopmental aspects of the disorder. This connection suggests that mitochondrial health may play a crucial role in the manifestation of ASD's core symptoms, such as difficulties in social interaction, communication challenges, and repetitive behavior patterns. Given the potential link between mitochondrial dysfunction and ASD, this study aims to utilize buccal swab samples to assess mitochondrial health in individuals with ASD. By analyzing mitochondrial function in a sample that is easy to obtain and does not cause harm is invasive, the study hopes to better understand the role of mitochondrial dysfunction in ASD. Our improved understanding of mitochondria function in ASD can lead to better and more effective ways to manage symptoms that create day-to-day set backs in an individuals life and creater more tailored intervention stategies.

Eligibility

Currently recruiting participants: Yes

Eligible gender: Male, Female, Transgender, Other

Eligible ages: 5 to 17

Accepts healthy participants: Yes

Inclusion criteria:

ASD Group:
1) Children aged 5-17 at the time of the visit with a diagnosis of autism and seen in consultation at the Child Development Centre.
2) Signed inform consent.
3) Willing & able to comply with study procedures

Control Group (Age-matched, sibling)
1) Aged 5-17yrs old
2) Parental consent and/or child assent
3) Willing & able to comply with study procedures

Exclusion criteria:

1) Antibiotic use 4 weeks prior to testing

Participate

Fill out the following form if you want to participate in this research

Method of contact

Additional information

Contact information

Tina Ram

Principal investigator:

Jane Shearer, Vice-Chair

Clinical trial:

No

REB-ID:

REB23-1557